Senhwa Biosciences, Inc.
6492
Rank in Stocks
#19529
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Share Price
$0.90843687
Last synced: 2026-11-10
Market Cap
$103.81M
Change (1 day)
-0.67%
Change (1 year)
-30.99%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Senhwa Biosciences, Inc. (6492)
Category
Healthcare
EPS for Senhwa Biosciences, Inc. (6492)
EPS as of June 2026 TTM: $-0.10
According to Senhwa Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-0.10. At the end of 2025 the company had an EPS of $-0.09, an increase over its 2024 EPS of $-0.10.
EPS history for Senhwa Biosciences, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.10 | 12.89% |
| 2025 | $-0.09 | -5.59% |
| 2024 | $-0.10 | -7.39% |
| 2023 | $-0.11 | -15.34% |
| 2022 | $-0.13 | -3.47% |
| 2021 | $-0.13 | -17.15% |
| 2020 | $-0.16 | -6.98% |
| 2019 | $-0.17 | 6.38% |
| 2018 | $-0.16 | -5.50% |
| 2017 | $-0.17 | 45.45% |
| 2016 | $-0.12 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -15,513.39% |
US
|
|
| $-7.07 | 6,858.66% |
US
|
|
| $-5.29 | 5,106.69% |
AU
|
|
| $12.88 | -12,777.26% |
BE
|
|
| $21.56 | -21,320.47% |
NL
|
Questions about Senhwa Biosciences, Inc.'s earnings per share (EPS)
What is Senhwa Biosciences, Inc.'s earnings per share (EPS)?
Senhwa Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-0.10, as of Jun 2026.
What was Senhwa Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Senhwa Biosciences, Inc.'s earnings per share (EPS) was $-0.09, compared with $-0.10 in 2024.
How has Senhwa Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Senhwa Biosciences, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.09) and lowest in 2020 ($-0.16).
How does Senhwa Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Senhwa Biosciences, Inc.'s earnings per share (EPS) ($-0.10) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.